A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with EGFR-mutated NSCLC and Acquired MET Amplification After Progression On a First-Line EGFR TKI By Ogkologos - January 16, 2026 431 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SACHI study Source RELATED ARTICLESMORE FROM AUTHOR Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Continues to Prolong EFS and OS in Patients with Stage II, IIIA, or IIIB (N2) NSCLC Patient Guide in Soft Tissue Sarcoma Now Available Also in Ukrainian Adjuvant Pembrolizumab Continues to Demonstrate Benefit in DFS and OS Among Patients with ccRCC MOST POPULAR Why Cancer Survivors Should Have a Written Survivorship Care Plan March 9, 2021 Studies Assess Impact of Cancer Risk-Reduction Measures for People with BRCA... April 15, 2024 Time to take on 9 new Cancer Grand Challenges March 8, 2023 EMA Recommends Extension of Indications for Ribociclib to Include Use in... November 5, 2024 Load more HOT NEWS FDA Approves Ivosidenib in Combination with Azacitidine for Newly Diagnosed AML Enhertu Improves Survival for Metastatic “HER2-Low” Breast Cancer Talquetamab Continuous To Demonstrate High Overall Response Rates in Heavily Pretreated... Judge Rules That 3-Year-Old Child With Leukemia Must Get Chemo Against...
